SUMAVEL DOSEPRO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sumavel Dosepro, and when can generic versions of Sumavel Dosepro launch?
Sumavel Dosepro is a drug marketed by Endo Operations and is included in one NDA. There are three patents protecting this drug.
This drug has fourteen patent family members in eight countries.
The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sumavel Dosepro
A generic version of SUMAVEL DOSEPRO was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUMAVEL DOSEPRO?
- What are the global sales for SUMAVEL DOSEPRO?
- What is Average Wholesale Price for SUMAVEL DOSEPRO?
Summary for SUMAVEL DOSEPRO
| International Patents: | 14 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 115 |
| Clinical Trials: | 1 |
| Patent Applications: | 2,223 |
| Drug Prices: | Drug price information for SUMAVEL DOSEPRO |
| What excipients (inactive ingredients) are in SUMAVEL DOSEPRO? | SUMAVEL DOSEPRO excipients list |
| DailyMed Link: | SUMAVEL DOSEPRO at DailyMed |
Recent Clinical Trials for SUMAVEL DOSEPRO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Synteract, Inc. | Phase 4 |
| Zogenix, Inc. | Phase 4 |
US Patents and Regulatory Information for SUMAVEL DOSEPRO
SUMAVEL DOSEPRO is protected by three US patents.
Patents protecting SUMAVEL DOSEPRO
Device for readying a needle free injector for delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Casing
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Device for readying a needle free injector for delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-002 | Nov 26, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUMAVEL DOSEPRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUMAVEL DOSEPRO
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
